Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

March 16, 2016March 16, 2016

People with Severe Asthma Are Focus of Study to Better Target Treatment of XolairR

Asthma, News

A new study developed by researchers at the National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit in England and managed by the NIHR-funded Clinical Trials Unit at the University of ... Read more

March 15, 2016March 16, 2016

For IPF Patients, Results Appear Promising in Phase 2 Study from FibroGen’s Investigative Drug

Idiopathic Pulmonary Fibrosis, News

FibroGen recently announced the publication of results from a Phase 2 clinical trial (NCT01262001) in patients with idiopathic pulmonary fibrosis (IPF), testing a 48-week treatment with the company’s investigational drug FG-3019, ... Read more

March 14, 2016March 14, 2016

Greater Risk for COPD, Other Diseases Found with High Coronary Artery Calcium Scores, Study Shows

COPD, Lung Cancer, News, Pneumonia

People with a high coronary artery calcium (CAC) score puts them at increased risk not only for heart and vascular disease, but also for chronic obstructive pulmonary disease (COPD), cancer, and chronic ... Read more

March 10, 2016March 16, 2016

Cystic Fibrosis Foundation Receives doTERRA Donation for Fundraising Banquet in North Carolina

Cystic Fibrosis, News

The Cystic Fibrosis Foundation‘s Sixth Annual STANDOUT Awards banquet, held in North Carolina, recognized business men and women in the Charlotte community and raise money for the Foundation. At the event, ... Read more

March 9, 2016March 16, 2016

Routine Assessment of COPD Patients’ Inhalers Is Important for Best Treatment, According to Research by Sunovion

News

Sunovion Pharmaceuticals recently announced data on health outcomes concerning the use of inhaler devices among patients with chronic obstructive pulmonary disease (COPD) at the Society of Hospital Medicine’s 2016 conference in ... Read more

March 8, 2016March 8, 2016

New Research into Cystic Fibrosis Lung Infections Could Pave Way to Better Treatments

Cystic Fibrosis, News

Recent research progress into how bacteria adapt and evolve in chronic lung infections in cystic fibrosis patients could lead to the development of improved treatment strategies, according to a new review ... Read more

March 7, 2016March 7, 2016

Two Phase 3 Trials for Asthma Drug Lebrikizumab Have Differing Results, Genentech Reports

Asthma, News

Genentech, a member of the Roche Group, recently reported top-line data from two Phase 3 clinical trials assessing the efficacy and safety of lebrikizumab in people with uncontrolled asthma despite ... Read more

March 4, 2016March 4, 2016

Actelion Emphasizes Commitment to Patients on Rare Disease Day

News, Pulmonary Hypertension

The theme of Rare Disease Day 2016, “Patient Voice — Join us in making the voice of rare diseases heard,” was a major cause for Switzerland-based Actelion, a leader in the field ... Read more

March 3, 2016March 16, 2016

Vertex Awards $1M in Grants to 18 Nonprofits for Cystic Fibrosis Initiatives

Cystic Fibrosis, News

Vertex Pharmaceuticals recently awarded the company’s 2016 Cystic Fibrosis (CF) Circle of Care grants to 18 medical, academic, and community organizations, totaling nearly $1 million. Now in its second year, the CF Circle of ... Read more

February 29, 2016March 16, 2016

Inventiva, Developer of Potential Therapy for Systemic Sclerosis, Awarded at 4th World Congress for Its Innovative Approach

Idiopathic Pulmonary Fibrosis, News, Scleroderma

Inventiva, a drug discovery company focused on the treatments of fibrotic, oncological, and rare diseases, announced that the organizing committee of the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, which ... Read more